

# PRODUCT INFORMATION



## BRAP (human, recombinant)

Item No. 45174

### Overview and Properties

**Synonyms:** BRAP23, BRCA1-associated Protein, Impedes Mitogenic Signal Propagation, IMP, Renal Carcinoma Antigen NY-REN-63, RING Finger Protein 52, RING-type E3 Ubiquitin Transferase BRAP2

**Source:** Active recombinant human BRAP expressed in *E. coli*

**Uniprot No.:** Q7Z569

**Molecular Weight:** 67.3 kDa

**Storage:** -80°C (as supplied)

**Stability:** ≥1 year

**Purity:** ≥90% estimated by SDS-PAGE

**Supplied in:** 50 mM Tris-HCl, pH 7.5, containing 200 mM sodium chloride and 20% glycerol

**Endotoxin Testing:** <1.0 EU/g, determined by the LAL endotoxin assay


**Protein Concentration:** *batch specific* mg/ml

**Activity:** *batch specific* U/ml

**Specific Activity:** *batch specific* U/mg


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Images




Lane 1: MW Markers  
Lane 2: BRAP (2 µg, reduced)  
Lane 3: BRAP (2 µg, non-reduced)

SDS-PAGE Analysis of BRAP. This protein has a calculated molecular weight of 67.3 kDa.



Lane 1: MW Markers  
Lane 2: BODIPY-Ub + UBE1 + UbcH5b + BRAP with ATP  
Lane 3: BODIPY-Ub + UBE1 + UbcH5b + with ATP  
Lane 4: BODIPY-Ub + UBE1 + UbcH5b + without ATP

The ubiquitin conjugating activity of BRAP was validated through its ability to catalyze the generation of polyubiquitin chains in the presence of the E1 activating enzyme UBE1, the E2 conjugating enzyme UbcH5b and BODIPY-ubiquitin. Incubation of BRAP for 60 minutes at 37°C in the presence of BODIPY-ubiquitin, UBE1, UbcH5b, and ATP (Lane 2) was compared alongside two control reactions with either BRAP (Lane 3) or BRAP + ATP (Lane 4) excluded from the reaction. Ubiquitin conjugates were identified by the migration of the BODIPY-ubiquitin band, and these were observed only in the presence of ATP and BRAP.



**WARNING**  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/04/2026

**CAYMAN CHEMICAL**  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM

# PRODUCT INFORMATION



## Description

---

BRCA1-associated protein (BRAP) is an E3 ubiquitin ligase with roles in the regulation of nuclear protein import and cell signaling.<sup>1</sup> It is composed of a nucleotide-binding  $\alpha/\beta$  plait, RING-finger, UBP-like zinc-finger (ZfUBP), and coiled-coil domain and localizes to the cytoplasm.<sup>1,2</sup> BRAP binds to a variety of transcription factors and kinases in the cytosol to both inhibit nuclear translocation and impede signal propagation. SNPs in *BRAP* are associated with an increased risk of myocardial infarction and with a predisposition to alcohol use disorder.<sup>3,4</sup> Cayman's BRAP (human, recombinant) protein can be used for enzyme activity and Western blot (WB) applications and has a calculated molecular weight of 67.3 kDa.

## References

---

1. Shoji, S., Hanada, K., Ohsawa, N., *et al.* Central catalytic domain of BRAP (RNF52) recognizes the types of ubiquitin chains and utilizes oligo-ubiquitin for ubiquitylation. *Biochem. J.* **474**(18), 3207-3226 (2017).
2. Fulcher, A.J., Roth, D.M., Fatima, S., *et al.* The BRCA-1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal. *FASEB J.* **24**(5), 1454-1466 (2010).
3. Ozaki, K., Sato, H., Inoue, K., *et al.* SNPs in BRAP associated with risk of myocardial infarction in Asian populations. *Nat. Genet.* **41**(3), 329-333 (2009).
4. Kim, J.W., Choe, Y.M., Shin, J.G., *et al.* Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the alcohol use disorders identification test. *Neuropsychiatr. Dis. Treat.* **15**, 83-94 (2018).

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM